title: Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).
abstract: BACKGROUND
  Since there are no randomized studies, the treatment of choice for patients with early stage lymphocyte-predominant Hodgkin's lymphoma (LPHL) remains unclear. We thus reviewed all LPHL cases registered in the database of the German Hodgkin Study Group (GHSG) and compared the different treatment approaches, such as extended field (EF), involved field (IF) radiation and combined modality (CM) treatment for LPHL stage IA patients.
  
  
  METHODS
  One hundred and thirty-one patients with LPHL in clinical stage IA without risk factors were analyzed. Forty-five patients were treated with EF radiotherapy, 45 patients with IF radiation and 41 patients received CM treatment. The median follow-up was 78 months in the EF group, 40 months after CM and 17 months after IF, respectively.
  
  
  RESULTS
  A total of 129 patients achieved complete remission (CR and CRu): 98% after EF radiotherapy, 100% after IF radiation and 95% after CM. With a median follow-up of 43 months there were 5% relapses and only three patients died. Toxicity of treatment was generally mild with most events observed after CM.
  
  
  CONCLUSIONS
  In terms of remission induction IF radiotherapy for stage IA LPHL patients is as effective as EF or CM treatment. However, longer follow-up is needed before final conclusion as the optimal therapy.
authors.affiliation: Clinic I for Internal Medicine, Clinic of Radiotherapy and Department of Radiology of University Hospital Cologne.
authors.forename: L
authors.initials: L
authors.lastname: Nogová
authors.forename: T
authors.initials: T
authors.lastname: Reineke
authors.forename: H T
authors.initials: HT
authors.lastname: Eich
authors.forename: A
authors.initials: A
authors.lastname: Josting
authors.forename: H K
authors.initials: HK
authors.lastname: Müller-Hermelink
authors.forename: K
authors.initials: K
authors.lastname: Wingbermühle
authors.forename: C
authors.initials: C
authors.lastname: Brillant
authors.forename: A
authors.initials: A
authors.lastname: Gossmann
authors.forename: J
authors.initials: J
authors.lastname: Oertel
authors.forename: M V
authors.initials: MV
authors.lastname: Bollen
authors.forename: R-P
authors.initials: RP
authors.lastname: Müller
authors.forename: V
authors.initials: V
authors.lastname: Diehl
authors.forename: A
authors.initials: A
authors.lastname: Engert
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D016208:Databases, Factual; D019583:Dose Fractionation, Radiation; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors